TY - JOUR
T1 - FGF21 regulates sweet and alcohol preference
AU - Talukdar, Saswata
AU - Owen, Bryn M.
AU - Song, Parkyong
AU - Hernandez, Genaro
AU - Zhang, Yuan
AU - Zhou, Yingjiang
AU - Scott, William T.
AU - Paratala, Bhavna
AU - Turner, Tod
AU - Smith, Andrew
AU - Bernardo, Barbara
AU - Müller, Christian P.
AU - Tang, Hao
AU - Mangelsdorf, David J.
AU - Goodwin, Bryan
AU - Kliewer, Steven A.
PY - 2016/2/9
Y1 - 2016/2/9
N2 - Fibroblast growth factor 21 (FGF21) is a hormone induced by various metabolic stresses, including ketogenic and high-carbohydrate diets, that regulates energy homeostasis. In humans, SNPs in and around the FGF21 gene have been associated with macronutrient preference, including carbohydrate, fat, and protein intake. Here we show that FGF21 administration markedly reduces sweet and alcohol preference in mice and sweet preference in cynomolgus monkeys. In mice, these effects require the FGF21 co-receptor β-Klotho in the central nervous system and correlate with reductions in dopamine concentrations in the nucleus accumbens. Since analogs of FGF21 are currently undergoing clinical evaluation for the treatment of obesity and type 2 diabetes, our findings raise the possibility that FGF21 administration could affect nutrient preference and other reward behaviors in humans.
AB - Fibroblast growth factor 21 (FGF21) is a hormone induced by various metabolic stresses, including ketogenic and high-carbohydrate diets, that regulates energy homeostasis. In humans, SNPs in and around the FGF21 gene have been associated with macronutrient preference, including carbohydrate, fat, and protein intake. Here we show that FGF21 administration markedly reduces sweet and alcohol preference in mice and sweet preference in cynomolgus monkeys. In mice, these effects require the FGF21 co-receptor β-Klotho in the central nervous system and correlate with reductions in dopamine concentrations in the nucleus accumbens. Since analogs of FGF21 are currently undergoing clinical evaluation for the treatment of obesity and type 2 diabetes, our findings raise the possibility that FGF21 administration could affect nutrient preference and other reward behaviors in humans.
UR - http://www.scopus.com/inward/record.url?scp=84957949211&partnerID=8YFLogxK
U2 - 10.1016/j.cmet.2015.12.008
DO - 10.1016/j.cmet.2015.12.008
M3 - Article
C2 - 26724861
AN - SCOPUS:84957949211
SN - 1550-4131
VL - 23
SP - 344
EP - 349
JO - CELL METABOLISM
JF - CELL METABOLISM
IS - 2
ER -